[
  {
    "ts": "2026-02-27T00:30:02+00:00",
    "headline": "Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.",
    "summary": "Even amid volatility, Pfizer keeps rewarding shareholders year after year.",
    "url": "https://www.barchart.com/story/news/457469/love-dividends-1-stock-to-buy-now-with-a-yield-over-6",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "5d1714c1-838c-330c-8f72-1f04a85bf9b1",
      "content": {
        "id": "5d1714c1-838c-330c-8f72-1f04a85bf9b1",
        "contentType": "STORY",
        "title": "Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.",
        "description": "",
        "summary": "Even amid volatility, Pfizer keeps rewarding shareholders year after year.",
        "pubDate": "2026-02-27T00:30:02Z",
        "displayTime": "2026-02-27T00:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82",
          "originalWidth": 1600,
          "originalHeight": 1054,
          "caption": "Money bag with the word Dividends by Andrii Yalanskyi via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8AbXQLuHyuWf6J2NZjhbww--~B/aD0xMDU0O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82.cf.webp",
              "width": 1600,
              "height": 1054,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ljd0Jvh1WDKM3R0BdHhrVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/457469/love-dividends-1-stock-to-buy-now-with-a-yield-over-6",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/love-dividends-1-stock-buy-003002196.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T05:07:26+00:00",
    "headline": "Novavax Q4 Earnings Call Highlights",
    "summary": "Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller, earlier-stage internal pipeline, while continuing to reduce operating expenses and stabilize the balan",
    "url": "https://www.marketbeat.com/instant-alerts/novavax-q4-earnings-call-highlights-2026-02-26/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "73442ed1-fe48-3d25-a4ff-d149dc7ecdb0",
      "content": {
        "id": "73442ed1-fe48-3d25-a4ff-d149dc7ecdb0",
        "contentType": "STORY",
        "title": "Novavax Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller, earlier-stage internal pipeline, while continuing to reduce operating expenses and stabilize the balan",
        "pubDate": "2026-02-27T05:07:26Z",
        "displayTime": "2026-02-27T05:07:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/06036d4683227ebf91b1ff6c594a32af",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Novavax logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hTdY6eLQqsZjWYovkoWMAQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/06036d4683227ebf91b1ff6c594a32af.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ls57TlEE2kRGYbXTMhEumA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/06036d4683227ebf91b1ff6c594a32af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/novavax-q4-earnings-call-highlights-2026-02-26/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novavax-q4-earnings-call-highlights-050726500.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T12:01:44+00:00",
    "headline": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for the first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer/mCRC. This decision converts a previous accelerated approval into a […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-secures-full-fda-120144586.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c2023d61-9bd2-366b-8986-5429356ab5db",
      "content": {
        "id": "c2023d61-9bd2-366b-8986-5429356ab5db",
        "contentType": "STORY",
        "title": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for the first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer/mCRC. This decision converts a previous accelerated approval into a […]",
        "pubDate": "2026-02-27T12:01:44Z",
        "displayTime": "2026-02-27T12:01:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b",
          "originalWidth": 640,
          "originalHeight": 427,
          "caption": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CncPfS_Mqj5tx.LtSIbZSQ--~B/aD00Mjc7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b.cf.webp",
              "width": 640,
              "height": 427,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kTdkjgY5eFmOS7TjNI_NNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-secures-full-fda-120144586.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-secures-full-fda-120144586.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T14:12:07+00:00",
    "headline": "Pfizer’s New BRAFTOVI Approval Broadens Oncology Reach And Investor Debate",
    "summary": "Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic colorectal cancer. The approval converts BRAFTOVI’s prior accelerated status to full approval and is supported by data from the global Phase 3 BREAKWATER trial. The decision recognizes benefits in both progression-free survival and overall survival for this aggressive colorectal cancer subtype. For...",
    "url": "https://finance.yahoo.com/news/pfizer-braftovi-approval-broadens-oncology-141207629.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "62bba406-d82c-35b4-8e7d-7ae86b29e792",
      "content": {
        "id": "62bba406-d82c-35b4-8e7d-7ae86b29e792",
        "contentType": "STORY",
        "title": "Pfizer’s New BRAFTOVI Approval Broadens Oncology Reach And Investor Debate",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic colorectal cancer. The approval converts BRAFTOVI’s prior accelerated status to full approval and is supported by data from the global Phase 3 BREAKWATER trial. The decision recognizes benefits in both progression-free survival and overall survival for this aggressive colorectal cancer subtype. For...",
        "pubDate": "2026-02-27T14:12:07Z",
        "displayTime": "2026-02-27T14:12:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-approval-broadens-oncology-141207629.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-approval-broadens-oncology-141207629.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T13:26:00+00:00",
    "headline": "Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates",
    "summary": "NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.",
    "url": "https://finance.yahoo.com/news/novavax-stock-gains-q4-earnings-132600264.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "964be80b-0061-3f2d-89a4-fbc7f0d04b1c",
      "content": {
        "id": "964be80b-0061-3f2d-89a4-fbc7f0d04b1c",
        "contentType": "STORY",
        "title": "Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates",
        "description": "",
        "summary": "NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.",
        "pubDate": "2026-02-27T13:26:00Z",
        "displayTime": "2026-02-27T13:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5ef34b229359328ddb52bd15cfa3b6b2",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mAJT8AI0XTvDvbozmsbubA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ef34b229359328ddb52bd15cfa3b6b2.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KWgXwT4.wkxg_6.ud1NMZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ef34b229359328ddb52bd15cfa3b6b2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novavax-stock-gains-q4-earnings-132600264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novavax-stock-gains-q4-earnings-132600264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T15:00:00+00:00",
    "headline": "PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer",
    "summary": "NEW YORK & TOKYO, February 27, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative",
    "url": "https://finance.yahoo.com/news/padcev-keytruda-cuts-risk-recurrence-150000295.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "076ffd20-a74d-3c8b-bc77-a39e564c6ba0",
      "content": {
        "id": "076ffd20-a74d-3c8b-bc77-a39e564c6ba0",
        "contentType": "STORY",
        "title": "PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer",
        "description": "",
        "summary": "NEW YORK & TOKYO, February 27, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative",
        "pubDate": "2026-02-27T15:00:00Z",
        "displayTime": "2026-02-27T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/da375dd0679497dde84fd49445e9d5b6",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v4m3rHAExaOtoo7K6ofvQQ--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/da375dd0679497dde84fd49445e9d5b6.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DCz7K9V.QyegMEvm1hQdfg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/da375dd0679497dde84fd49445e9d5b6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/padcev-keytruda-cuts-risk-recurrence-150000295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/padcev-keytruda-cuts-risk-recurrence-150000295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4503.T"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]